Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Positron's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 14.67.
Positron's Days Inventory for the
three
months ended in Jun. 2026 was 164.59.
Positron's Days Payable for the
three
months ended in Jun. 2026 was 165.19.
Therefore, Positron's Cash Conversion Cycle (CCC) for the
three
months ended in Jun. 2026 was 14.07.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Positron Cash Conversion Cycle Related Terms
Positron Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Positron's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
POSC vs XTNT, COCH, SRTS: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Positron's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Positron Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Positron's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Positron's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Positron's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Positron (POSC) has a Cash Conversion Cycle of 14.07 as of Jun. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Positron and its competitors.
Is Positron's Cash Conversion Cycle too high?
Positron's current Cash Conversion Cycle is 14.07. The Medical Devices & Instruments industry median Cash Conversion Cycle is 158.69. Positron's value of 14.07 is 91.1% below this industry median. Overall, Positron has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Positron's Cash Conversion Cycle compare to XTNT and COCH?
Positron's Cash Conversion Cycle of 14.07 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 158.69. Positron's value of 14.07 is 91.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 158.69, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Positron's current Cash Conversion Cycle of 14.07 is 91.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Positron and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 158.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Positron's current Cash Conversion Cycle is 14.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Positron stock overvalued right now?
Based on GuruFocus' analysis, Positron (POSC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.22, compared to a current price of $1.79 — trading 713.6% above its estimated fair value. The current Cash Conversion Cycle is 14.07 and 91.1% below the Medical Devices & Instruments industry median of 158.69. Positron's overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Positron (POSC), the current Cash Conversion Cycle is 14.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Positron (POSC) Overvalued in 2026?
Based on GuruFocus' analysis, Positron stock appears to be overvalued.
The current stock price of $1.79 is trading 713.6% above its estimated GF Value™ of $0.22.
GuruFocus considers Positron to be Significantly Overvalued.
Key valuation signals for POSC:
Cash Conversion Cycle: 14.07
GF Value™: $0.22 vs. price of $1.79 (713.6% above fair value)
Industry Position: 91.1% below the Medical Devices & Instruments median
No single metric tells the full story. See the POSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Positron Corp is a medical technology company engaged in the co-development, manufacture, and sale of PET and PET-CT imaging systems, delivering high-performance, cost-effective molecular imaging solutions that empower healthcare providers to improve the diagnosis and treatment of cardiovascular disease and other critical conditions. By combining proprietary PET and PET-CT systems with comprehensive clinical and technical support, flexible financing, & a focus on operational efficiency, Positron makes advance diagnostic imaging more accessible & sustainable for hospitals, outpatient centers, & physician practices. The company focused on advancing positron emission tomography imaging through the development, manufacture, & commercialization of PET & PET-computed tomography imaging systems.
22GF Score
Get the complete analysis for POSC
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
POSC has been successfully added to your 
